EX-99.1 2 ea030353001ex99-1.htm PRESS RELEASE, DATED AUGUST 27, 2026 Exhibit 99.1 NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED™ Platform Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED™ Revenue Expected to be Recognized in the Current Fiscal Quarter EDEN PRAIRIE, Minn. - August 27, 2026 - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today reported the successful completion of three separate large-animal procedures using its next-generation StereoCED™ platform. In two of the three procedures, NeuroOne’s drug delivery electrodes both delivered a study agent directly into targeted brain tissue and recorded intracranial electrophysiological activity from the same targeted regions. This is a combination the Company believes has not been previously demonstrated and represents a first in the field of convection-enhanced delivery. The procedures …
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
NeuroOne Medical Technologies Corporation
NMTCNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On August 27, 2026, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing that three procedures in large animals were performed using the Company’s StereoCED™ platform. A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Company context
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.